|
FDA Will Accept Interim Trial Data To Support Provenge's Efficacy
The FDA informed Dendreon that it would accept interim data from a long-term clinical trial for investigational prostate cancer treatment Provenge to fulfill the agency’s request for additional efficacy data before approving the product, the company said.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives